Nuclera and Danaher-owned US ally boost protein proposition
Nuclera is accelerating protein expression and optimisation through its benchtop eProtein Discovery™ System. This collaboration is focused on accelerating the production, purification and characterisation of proteins required for drug research and development, enabled through the combination of Nuclera’s eProtein Discovery System with Cytiva’s Biacore™ surface plasmon resonance (SPR) technology.
Proteins represent 95 per cent of drug targets designed to combat disease. Rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development. Typically, it takes months to obtain and characterise proteins but Nuclera and Cytiva together have achieved production and characterisation within five days.
This achievement was showcased at industry conferences Discovery on Target and PEGS Europe, where Nuclera’s eProtein Discovery System was used to produce Bruton's Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF). These proteins were subsequently functionally characterised using Cytiva’s Biacore SPR system.
Dr. Yvonne Tan, Associate Director of Product Management, Nuclera, said: “Collaborating with life science leader Cytiva supports Nuclera in our mission of improving human health. Through this collaboration, we have demonstrated eProtein Discovery’s ability to produce clinically significant proteins that can be used in characterisation experiments.
“Combining eProtein Discovery’s capability to streamline protein production workflows with Cytiva’s Biacore protein characterisation systems open a whole new avenue for accelerating drug development.”
Anna Moberg, Senior Manager and Project Manager, Cytiva, added: “The ability of Nuclera’s eProtein Discovery to accelerate protein production and purification complements Cytiva’s Biacore SPR technology by streamlining the upstream protein production process. We look forward to continuing our collaboration to further enhance the production of characterisable proteins for drug development.”
Cytiva owner Danaher paid $5.7 billion to acquire Cambridge based Abcam at the end of 2023.